At a glance
ClinicalIndex Comparison Record- ✓Newly diagnosed Group B intraocular retinoblastoma in one or both eyes, or Group A in one eye with Group B in the other, or enucleated Group E in one eye with Group B in the remaining eye
- ✓Confirmed diagnosis by CT/MRI of brain and orbits plus ophthalmologic evaluation under anesthesia within 3 weeks
- ✓No choroidal or optic nerve invasion past the lamina cribosa
- ✓No extraocular retinoblastoma on imaging or clinical exam
- ✕Prior chemotherapy for any indication
- ✕Prior radiotherapy for any indication
- ✕Prior local ophthalmic therapy for retinoblastoma
- ✕Any other prior therapy for retinoblastoma
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Trial of Systemic Neoadjuvant Chemotherapy for Group B Intraocular Retinoblastoma
In Brief
A Phase 3 clinical trial evaluating Carboplatin, Cryosurgery, and 5 other interventions for Intraocular Retinoblastoma. Completed, enrolled 28 participants across 10 sites.
Detailed Summary
This phase III trial is studying how well giving carboplatin and vincristine together with standard local ophthalmic therapy works in treating children with intraocular retinoblastoma. Drugs used in chemotherapy, such as carboplatin and vincristine, work in different ways to stop tumor from dividing so they stop growing or die. It is not yet known whether neoadjuvant chemotherapy combined with standard local ophthalmic therapy is effective in treating intraocular retinoblastoma.
Study Details
Timeline
Interventions
Given IV
Undergo radioactive therapy
Undergo radioactive therapy
Undergo radioactive therapy
Given IV